XML 64 R51.htm IDEA: XBRL DOCUMENT v3.24.3
Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)
$ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Jan. 31, 2010
cvr
Sep. 30, 2024
USD ($)
Sep. 30, 2023
USD ($)
Sep. 30, 2024
USD ($)
Sep. 30, 2023
USD ($)
Dec. 31, 2023
USD ($)
Sep. 18, 2023
contract
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Derivative Asset Statement Of Financial Position Extensible Enumeration Not Disclosed Flag       Derivative assets(2)   Derivative assets(2)  
Number of CVR series | cvr 4            
Agenus Partnered Program              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Percentage of milestones (as a percent)             50.00%
Agenus Partnered Program | Discount Rate              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Discount rate (as a percent)           0.25  
Agenus Partnered Program | Primordial Genetics              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Number of contracts | contract             2
Transferred over Time | Phase 3 clinical trial              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Gross contract asset   $ 10,000   $ 10,000      
Minimum | Agenus Partnered Program | Discount Rate              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Discount rate (as a percent)   0.15   0.15      
Maximum | Agenus Partnered Program | Discount Rate              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Discount rate (as a percent)   0.25   0.25      
Maximum | Transferred over Time | Development, regulatory, & commercial milestones and tiered royalties              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Investments   $ 375,000   $ 375,000      
Metabasis              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Number of CVRs issued per acquiree share | cvr 4            
Number of CVRs issued from each CVR series | cvr 1            
Frequency of cash payments to CVR holders 6 months            
(Decrease) increase of mark-to-market adjustment of CVR liability   (200) $ (100) 900 $ 2    
Recurring              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Investment in Viking common stock   63,310   63,310   $ 32,185  
Derivative asset   30,379   30,379   3,531  
Total assets   186,403   186,403   150,886  
Total liabilities   3,991   3,991   3,198  
Recurring | Short-term investments, excluding Viking              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Investments, fair value   92,714   92,714   115,170  
Recurring | Contingent liabilities | CyDex              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Contingent liabilities   223   223   320  
Recurring | Contingent liabilities | Metabasis              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Contingent liabilities   3,768   3,768   2,878  
Recurring | Level 1              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Investment in Viking common stock   63,310   63,310   32,185  
Derivative asset   0   0   0  
Total assets   82,885   82,885   39,476  
Total liabilities   0   0   0  
Recurring | Level 1 | Short-term investments, excluding Viking              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Investments, fair value   19,575   19,575   7,291  
Recurring | Level 1 | Contingent liabilities | CyDex              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Contingent liabilities   0   0   0  
Recurring | Level 1 | Contingent liabilities | Metabasis              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Contingent liabilities   0   0   0  
Recurring | Level 2              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Investment in Viking common stock   0   0   0  
Derivative asset   0   0   0  
Total assets   73,139   73,139   107,879  
Total liabilities   3,768   3,768   2,878  
Recurring | Level 2 | Short-term investments, excluding Viking              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Investments, fair value   73,139   73,139   107,879  
Recurring | Level 2 | Contingent liabilities | CyDex              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Contingent liabilities   0   0   0  
Recurring | Level 2 | Contingent liabilities | Metabasis              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Contingent liabilities   3,768   3,768   2,878  
Recurring | Level 3              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Investment in Viking common stock   0   0   0  
Derivative asset   30,379   30,379   3,531  
Total assets   30,379   30,379   3,531  
Total liabilities   223   223   320  
Recurring | Level 3 | Short-term investments, excluding Viking              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Investments, fair value   0   0   0  
Recurring | Level 3 | Contingent liabilities | CyDex              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Contingent liabilities   223   223   320  
Recurring | Level 3 | Contingent liabilities | Metabasis              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Contingent liabilities   $ 0   $ 0   $ 0